CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction

Condition(s) studied

Investigational drug(s) / intervention(s)

HFpEF Observational Measurements: Observational measurements including collection of blood for biomarker and genetic analyses, echocardiography, ECG, and extraction of clinical data from electronic health records (comorbidities, medications, and prior hospitalizations). No treatment or procedure is assigned; all data reflect routine care and participant characteristics.

Study summary

The goal of this observational study is to improve early detection, characterization, and understanding of heart failure with preserved ejection fraction (HFpEF) in adults at risk of or diagnosed with HFpEF, including men and women across Danish regions.

The main questions to answer are:

Can systematic cardiovascular screening and deep phenotyping improve early identification and classification of HFpEF?

Which clinical, imaging, biomarker, and metabolic characteristics define subtypes (phenotypes) of HFpEF and predict disease progression and outcomes?

Researchers will compare participants with HFpEF, participants at risk of HFpEF, and relevant control groups to see if differences in biomarkers, imaging findings, and clinical characteristics can identify early disease stages and distinct HFpEF phenotypes.

Participants identified with HFpEF will:

* Undergo detailed cardiovascular examinations (e.g., echocardiography, CT and other imaging examinations, RHC, CPET)
* Provide blood and tissue samples for biomarker and metabolic analyses
* Complete clinical assessments and questionnaires
* Have relevant health data collected from national health registries
* Attend follow-up assessments to monitor disease progression

Eligibility

Primary outcome measure(s)

• Early identification of HFpEF — baseline, pre-intervention
  Proportion (%) of individuals identified through the screening procedures outlined in the protocol among the target population.

Trial sites (1)

More Herlev and Gentofte Hospital trials in Denmark

Other trials for the same condition